- Research article
- Open Access
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
© Bearz et al.; licensee BioMed Central Ltd. 2012
Received: 27 October 2011
Accepted: 23 August 2012
Published: 3 September 2012
Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment.
We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment.
Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively.
In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.
The current standard of care in the management of advanced malignant pleural mesothelioma is a platinum-based chemotherapy; a number of phase II trials have suggested an activity for cisplatin and gemcitabine combination[2, 3], while the landmark trial is the one by Vogelzang and Colleagues comparing cisplatin plus pemetrexed to cisplatin alone, demonstrating a survival benefit for the combination of 2.8 months versus cisplatin alone. A subsequent trial showed a 2.6-month improvement in overall survival (OS) for the combination with cisplatin and raltitrexed versus cisplatin alone, 11.4 versus 8.8 months, respectively. Although carboplatin has been shown to be less effective than cisplatin in other malignancies like Non Small-Cell Lung Cancer (NSCLC), when cisplatin is contraindicated for comorbidities, it may be replaced by carboplatin; moreover several phase I and II trials where carboplatin was combined with pemetrexed or gemcitabine in malignant mesothelioma have given interesting results[7–9]. Due to similar histologic features, treatment for peritoneal mesothelioma has followed the same recommendations[10, 11].
No activity for second-line treatment has been clearly reported in patients affected by malignant pleural mesothelioma; pemetrexed alone or combined with platin has shown efficacy even in patients previously treated with other drugs than pemetrexed[12, 13], and some activity has been demonstrated for vinorelbine.
In absence of a standard second-line treatment for malignant mesothelioma, we hypothesized efficacy from re-treatment with pemetrexed alone or in combination with platin, when time to progression (TTP), calculated from the end of first-line chemotherapy and radiologic evidence of progression, was greater or equal than 6 months, as suggested for other pathologies with few therapeutic options. We performed a retrospective analysis of patients re-treated with pemetrexed-based therapy in second line, to assess our hypothesis.
We retrospectively collected patients affected by mesothelioma from several Italian Institutions (IRCCS-Aviano, IRCCS-S. Raffaele Milan, and General Hospitals of Verona, Gorizia, Udine, Mirano, and Padova), after obtaining approval from IRCCS – Aviano internal ethics committee. In all these Institutions there was the policy to re-treat all patients affected by advanced malignant mesothelioma with the same drugs used in first line, when certain features were observed. Patients had to be treated with a pemetrexed-platin combination as first-line chemotherapy, obtaining partial response (PR) or stable disease (SD), with a further TTP greater or equal than 6 months. We analyzed characteristics and outcome only of those patients treated again with a pemetrexed-based therapy after progression.
The regimens administered as re-treatment were pemetrexed at a dose of 500 mg/m2 combined with a platinum compound (cisplatin at a dose of 75 mg/m2 or carboplatin at an area under the plasma concentration-time curve –AUC - of 5 mg/ml/min) every three weeks or pemetrexed single agent at a dose of 500 mg/m2 every three weeks, using standard vitamin supplementation and dexamethasone prophylaxis. All the patients had a calculated creatinine clearance value (according to Cockcroft and Gault formula) greater than 45 mL/min, and good hepatic and bone marrow activity. Before re-treatment, all the patients were studied with a chest and abdomen CT scan, repeated every two cycles. Responses were evaluated through RECIST modified criteria for mesothelioma. Information on survival was obtained through an active follow-up based on verification of vital status of the patients, and survival analysis was measured from the date of the first pemetrexed-based re-treatment to death. If survival status was unknown at the final follow-up, OS time was censored at the last contact date. TTP was measured from the beginning of second line of therapy to second relapse. OS and TTP analyses were computed by the Kaplan-Meier method, and log-rank test was used to test the difference between subgroups of treatment. In all cases, statistical significant was claimed for ≤0.05.
Characteristics of 30 patients with malignant mesothelioma and retreated with pemetrexed-based therapy as second-line therapy
N. of patients
---Palliative pleural decortications
---Videothoracoscopy and pleurodesis
Median age (years) (range)
Performance Status (ECOG):
Stage at diagnosis (IMIG):
Combination of first-line chemotherapy:
---Cisplatin and pemetrexed
---Carboplatin and pemetrexed
Response to first-line treatment:
Efficacy of re-treatment with pemetrexed-based chemotherapy in 30 patients affected by malignant mesothelioma
N. of patients
Regimen of re-treatment:
---Cisplatin + pemetrexed
---Carboplatin + pemetrexed
---Absence of pain (before treatment and after)
Median number of cycles at re-treatment was 4 (range: 3–9). The combination of choice was carboplatin plus pemetrexed in 16 patients (53%), pemetrexed alone was chosen in 9 patients (30%), and 5 patients (17%) received cisplatin and pemetrexed again as they received for first-line.
Modified RECIST criteria were available for 26 patients out of 30; for three patients progression was due to a relapse of pleural effusion and in one patient the retrieval of the radiological images was not possible. Response rate after re-treatment was as follows: 10 patients showed progression of disease (33%), most of patients had stability of disease, 15 out of 30 patients (50%), while 5 patients showed a partial response (17%); median duration of stable disease in patients being retreated was 4.7 months.
We also collected information during re-treatment about symptom control, based on VAS patient global assessment[19, 20]; all the Institutions were involved in a monitoring program to ensure pain control, therefore VAS administration was part of routine care. Pain decreased in 13 out of 30 patients (43%), 7 patients (23%) had no pain at all, while 10 patients (33%) reported a worsening of their pain.
Malignant mesothelioma is a very aggressive disease with poor outcome even when radical surgery is possible; palliative chemotherapy is offered when patients are not candidate for curative surgery; in randomized clinical trials a platin-combination with pemetrexed or raltitrexed have given better results[4, 5]. Out of those combinations, there are no recommended salvage therapies, when patients experience a progression. For other malignancies, when progression occurs at least 6 months after the end of previous treatment, a re-challenge with the same drugs is offered because an antiblastic activity is considered still possible. Based on the lack of alternatives and in analogy with other malignancies, we proposed a re-treatment with the same therapy used as first-line for patients affected by advanced mesothelioma and progressed after obtaining a benefit from first-line combination with platin and pemetrexed. We collected data about 30 patients from several Italian institutions, where the same policy was applied. We found that re-treatment with pemetrexed was feasible in all our patients; a more frequent combination of pemetrexed with carboplatin instead of cisplatin was chosen, likely due to an effort to avoid neurologic or nephrologic toxicities from cisplatin. Once again an interesting response was obtained, with a clinical benefit observed in 20 out of 30 patients (disease control rate, DCR, 66%, PR and SD), both by radiological assessment and reduction of pain. Overall TTP and survival were promising for a second-line setting of patients with advanced mesothelioma, 5.1 and 13.6 months, respectively, considering other similar reports from the literature: a French cohort, where several different drugs were used in second-line for patients affected by mesothelioma, showed 3.8 and 12.2 months, respectively for TTP and OS, while in a mono-institutional Italian cohort salvage therapy with gemcitabine-platin combination in second or further line demonstrated 3 and 5.5 months, respectively as TTP and OS. We are aware that our group of patients was selected for good prognostic factors, such as PS, benefit after first-line treatment (SD or RP) and a quite long TTP after the end of first-line treatment; moreover no patient was affected by pure sarcomatoid histotype, considered one of the worst prognostic factors[23, 24]. We found a slightly better trend in TTP for patients treated with a platin-pemetrexed combination even at re-treatment; however, the difference was not statistically significant, and could just underline a better PS or younger age at the base of treatment choice.
At the time of preparation of this manuscript it has been just published a similar experience by Ceresoli and Colleagues. They collected data about a similar casistic of patients, 31 patients, treated in a single Institute. Their population was a little different for the inclusion criteria they set up for re-treatment with the same drugs used as first-line, choosing to re-treat with a pemetrexed-based therapy all the patients with a time to progression greater or equal than 3 months after the end of first line. In the Ceresoli’s paper, almost half of patients were re-treated with pemetrexed-combination as second-line, and half as further line of therapy, while all our patients received pemetrexed alone or in combination with a platin compound as second-line therapy only.
The difference in TTP after first-line as inclusion criteria and pemetrexed-based re-treatment used beyond second-line in almost half of the collected patients may explain the shorter TTP and OS observed in Ceresoli’s patients than in ours, 3.8 months and 5.1, respectively, although any significant comparison can be drawn between the two groups of patients.
Interestingly there are two papers, Ceresoli’s and ours, with similar results. Our patients consistently support the data from Ceresoli and Colleagues and strengthen the results, also for the homogenously use of pemetrexed-based re-treatment as second-line and the multi-institutional collection of data. When patients had a benefit from a platin-pemetrexed combination, in the absence of other effective strategies, we strongly suggest a re-treatment with the same drugs, because an improvement of the symptoms and a consistent gain in TTP can be still obtained.
The authors are indebted to Mrs Paola Favetta for her help in medical writing.
The authors thank all the patients and their families.
- Lee CW, Murray N, Anderson H, Rao SC, Bishop W: Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer. 2009, 64: 308-313. 10.1016/j.lungcan.2008.09.008.PubMedView ArticleGoogle Scholar
- Byrne M, Davidson J, Musk A, Dewar J, van Hazel G, Buck M: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999, 17: 25-30.PubMedGoogle Scholar
- Nowak A, Byrne M, Williamson R, Ryan G, Segal A, Fielding D: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002, 87: 491-496. 10.1038/sj.bjc.6600505.PubMedPubMed CentralView ArticleGoogle Scholar
- Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21: 2636-2644. 10.1200/JCO.2003.11.136.PubMedView ArticleGoogle Scholar
- Van Meerbeck J, Gaafar R, Manegold C, Van Klaveren R, Van Marck E, Vincent M: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of European Organisation for Reasearch and Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada. J Clin Oncol. 2005, 23: 6681-6689.View ArticleGoogle Scholar
- Ardizzoni A, Boni L, Tiseo M, Fossella F, Schiller J, Paesmans M: Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007, 99: 847-857. 10.1093/jnci/djk196.PubMedView ArticleGoogle Scholar
- Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol. 2002, 20: 3533-3544. 10.1200/JCO.2002.10.073.PubMedView ArticleGoogle Scholar
- Ceresoli G, Zucali P, Favaretto A, Grossi F, Bidoli P, Del Conte G: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006, 24: 1443-1448. 10.1200/JCO.2005.04.3190.PubMedView ArticleGoogle Scholar
- Favaretto A, Aversa S, Paccagnella A, Vde Manzini P, Palmisano V, Oniga F: Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicenter phase II study. Cancer. 2003, 97: 2791-2793. 10.1002/cncr.11405.PubMedView ArticleGoogle Scholar
- Byrne MJ, Davidson JA, Musk AW, Dewar J, von Hazel G, Buck M: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999, 17: 25-30.PubMedGoogle Scholar
- Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA: Open-label study of pemetrexed alone in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005, 7: 40-46. 10.3816/CLC.2005.n.020.PubMedView ArticleGoogle Scholar
- Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA: Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thor Oncol. 2006, 1: 506-512. 10.1097/01243894-200607000-00002.View ArticleGoogle Scholar
- Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C: Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma. J Clin Oncol. 2008, 26: 1698-1704. 10.1200/JCO.2006.09.9887.PubMedView ArticleGoogle Scholar
- Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000, 18: 3912-3917.PubMedGoogle Scholar
- Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E: Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. Lung Cancer. 2011, 2011 (72): 378-383.View ArticleGoogle Scholar
- Byrne MJ, Nowak K: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004, 15: 257-260. 10.1093/annonc/mdh059.PubMedView ArticleGoogle Scholar
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159/000180580.PubMedView ArticleGoogle Scholar
- Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481. 10.1080/01621459.1958.10501452.View ArticleGoogle Scholar
- Huskisson EC: Measurement of pain. Lancet. 1974, 2: 1127-1131.PubMedView ArticleGoogle Scholar
- Mccormack HM, Horne DJ, Sheather S: Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988, 18: 1007-1119. 10.1017/S0033291700009934.PubMedView ArticleGoogle Scholar
- Margery J, Riviere F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffie P: Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005–2006). Rev Pneumol Clin. 2010, 66: 255-259. 10.1016/j.pneumo.2010.07.013.PubMedView ArticleGoogle Scholar
- Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A: Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. Lung Cancer. 2011, 73: 351-355. 10.1016/j.lungcan.2011.01.005.PubMedView ArticleGoogle Scholar
- Schramm A, Opitz I, THies S, Seifert B, Moch H, Weder B, Soltermann A: Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2010, 37: 566-572. 10.1016/j.ejcts.2009.08.027.PubMedView ArticleGoogle Scholar
- Baas P: Predictive and prognostic factors in malignant pleural mesothelioma. Curr Opin Oncol. 2003, 15: 127-130. 10.1097/00001622-200303000-00002.PubMedView ArticleGoogle Scholar
- Ceresoli G, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A: Retreatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011, 72: 73-77. 10.1016/j.lungcan.2010.12.004.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.